Skip to main content

Arbutus Biopharma Corp 8-K, filed Oct 22, 2026

Arbutus Biopharma Corp (ABUS)

8-K 2026-10-22 For: 2026-10-20
View Original
Added on October 22, 2026

About this 8-K

Arbutus Biopharma Corp filed this 8-K on October 22, 2026, reporting on events of October 20, 2026.

The FDA notified the company that the clinical hold on the IND application for AB-101, its oral PD-L1 inhibitor, has been removed, allowing additional clinical development in the United States. Arbutus is evaluating next steps for AB-101's continued development. AI summary

Items reported

  • Item 8.01: Other events
  • Item 9.01: Financial statements and exhibits